This was demonstrated by Tan et al. [482] where apoptotic sensitivity to paclitaxel could be restored in H-Ras/ERK-dependent tumor cells, by treatment with the proteasome inhibitor bortezomib that promoted Bim-dependent tumor regression [482]. The gene discussed is MAPK1; the disease is neoplasm.